### Machine Learning for PK/PD Modeling in Drug Development

[Read more](https://www.certara.com/blog/machine-learning-for-pk-pd-modeling-in-drug-development/)

### How the US FDA MIDD paired pilot program helps sponsors

[Read more](https://www.certara.com/blog/how-the-us-fda-midd-paired-pilot-program-helps-sponsors/)

### Gain Nonclinical Drug Safety Insights with Real-Time Data Analysis

[Read more](https://www.certara.com/blog/gain-nonclinical-drug-safety-insights-with-real-time-data-analysis/)

### Measuring metabolites in index clinical DDI studies

[Read more](https://www.certara.com/blog/measuring-metabolites-in-index-clinical-ddi-studies/)

### Key development considerations for cell therapies

[Read more](https://www.certara.com/blog/development-considerations-cell-therapies/)

### PBPK Modeling to Support Bioequivalence & Generic Product Approvals

[Read more](https://www.certara.com/blog/pbpk-modeling-to-support-bioequivalence-generic-product-approvals/)